Multi-center, Single Blinded, RCT, Pivotal Study Efficacy and Safety of DTx to Improve ADHD
This study is completed in South Korea. It focuses on ADHD.
Key information made simple
What is this study testing?
This study is testing whether DTx may be useful for children experiencing ADHD.
What would participation involve?
Participants may receive DTx, attend study visits with the research team. The registry lists locations in South Korea.
Who is it mainly for?
This study appears to be mainly for children with ADHD. Because it involves minors, a parent or guardian may need to be involved.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, what role parents or guardians have in the process.
Your next step
The official record suggests a mix of remote and in-person participation through a clinic, with sites including Emotiv in Seoul. Participation appears to involve guided sessions or support activities with check-ins on how they fit into daily life. The main fit is usually matching the main diagnosis, while common reasons not to take part include safety concerns that need urgent care first and other factors that could make participation unsuitable. The official record does not list a formal phase, which usually means this is focused more on feasibility, delivery, or support than a standard drug-development stage.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
- Recruitment status
- Completed
- Estimated enrollment
- Not clearly listed
- Sponsor
- EMOTIV
- Sponsor type
- Unknown or unclear
- Study type
- Device
- Intervention type
- Device / app / digital / technology
- Study phase
- Not clearly listed
- Locations
- South Korea
- Age range
- From 6 Years to 12 Years
- Official registry ID
- NCT07173439
- Official title
- Multi-center, Single Blinded, RCT, Pivotal Study to Evaluate the Efficacy and Safety of DTx to Improve ADHD
- Official source
- Official registry link
Want help reviewing this study?
For you
Taking part may give access to a new approach being evaluated.
It requires regular follow-up, often through questionnaires or interviews.
Mixes in-person and remote participation.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring digital app or tool for people with adhd. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a device, app, or technology?
This appears to be a device / app / digital / technology study. The phase is not clearly listed in the public registry. Phase is mostly relevant for medication studies and some device studies. For this study, it may be more useful to look at what is required, the duration, visits, and eligibility criteria.
Who might this study be for?
This study may concern people with adhd; age range: From 6 Years to 12 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to use a device, app, or digital tool for a defined period. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What should I check about data, monitoring, alerts, and daily use?
If the study uses a device, app, or digital tool, check what data is collected, who can access it, how often you need to use it, and what happens if the tool detects a concerning signal. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by EMOTIV, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The registry indicates that this study is completed. It may still be useful for understanding the research, but you are unlikely to be able to join.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me
